Absence of anti-hepatitis B surface antibody after vaccination does not necessarily mean absence of immune response

被引:19
作者
Greub, G [1 ]
Zysset, F
Genton, B
Spertini, F
Frei, PC
机构
[1] CHU Vaudois, Div Immunol & Allergy, CH-1011 Lausanne, Switzerland
[2] CHU Vaudois, Div Prevent Hosp Med, CH-1011 Lausanne, Switzerland
[3] Univ Lausanne, Med Poliklin, Travel Clin, CH-1011 Lausanne, Switzerland
关键词
hepatitis B vaccine; anti-hepatitis B surface antibody; hepatitis B infection; serology;
D O I
10.1007/s430-001-8024-0
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
A small number of subjects vaccinated against hepatitis B do not produce anti-hepatitis B surface (HBs) antibody levels detectable by commercial assays. Others lose detectable anti-HBs at some time after vaccination. The absence of clinical hepatitis despite potential exposure to hepatitis B virus (HBV) in both kinds of subjects suggests that they might be protected by low antibody levels. However, besides anti-HBs, T helper response and memory cells which may be induced by the vaccine are certainly also important for immunity against HBV. In the present study, samples from vaccinated subjects, found to be anti-HBs negative in an initial assay, subsequently showed positive results in, respectively, 25%, 36% and 38% of the cases, when a second, third and fourth assay was used. In addition, 360 samples from "nonresponders" and from vaccinees who had lost anti-HBs, the reactivity of which was under the enzyme-linked immunoassay-cut-off value were compared to that of nonvaccinated controls. The absorbances were found to be significantly higher in the nonresponders (0.038) and in the vaccinees having lost anti-HBs (0.041), than in the controls (0.025). Such findings contribute to explaining why so-called nonresponders as well as vaccinees who have lost anti-HBs nevertheless appear to be protected.
引用
收藏
页码:165 / 168
页数:4
相关论文
共 17 条
[1]   HEPATITIS-B IN A NONRESPONDER TO HEPATITIS-B VACCINE [J].
BORTOLOTTI, F ;
REALDI, G ;
CRIVELLARO, C ;
PORNARO, E .
INFECTION, 1988, 16 (02) :119-120
[2]   IMMUNOGENICITY OF A RECOMBINANT PRE-S2-CONTAINING HEPATITIS-B VACCINE VERSUS PLASMA-DERIVED VACCINE ADMINISTERED AS A BOOSTER [J].
BUCHER, B ;
FRANCIOLI, P ;
GEUDELIN, B ;
FRITZELL, B ;
LAVANCHY, D ;
FREI, PC .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1994, 13 (03) :212-217
[3]   VACCINE-INDUCED ESCAPE MUTANT OF HEPATITIS-B VIRUS [J].
CARMAN, WF ;
ZANETTI, AR ;
KARAYIANNIS, P ;
WATERS, J ;
MANZILLO, G ;
TANZI, E ;
ZUCKERMAN, AJ ;
THOMAS, HC .
LANCET, 1990, 336 (8711) :325-329
[4]   12-YEAR FOLLOW-UP-STUDY OF HEPATITIS-B IMMUNIZATION OF SENEGALESE INFANTS [J].
COURSAGET, P ;
LEBOULLEUX, D ;
SOUMARE, M ;
LECANN, P ;
YVONNET, B ;
CHIRON, JP ;
COLLSECK, AM ;
DIOPMAR, I .
JOURNAL OF HEPATOLOGY, 1994, 21 (02) :250-254
[5]   Anti-HBs responses in children vaccinated with different schedules of either plasma-derived or HBV DNA recombinant vaccine [J].
DaVilla, G ;
Pelliccia, MG ;
Peluso, F ;
Ricciardi, E ;
Sepe, A .
RESEARCH IN VIROLOGY, 1997, 148 (02) :109-114
[6]   THE PREVENTION OF HEPATITIS-B WITH VACCINE - REPORT OF THE CENTERS-FOR-DISEASE-CONTROL MULTI-CENTER EFFICACY TRIAL AMONG HOMOSEXUAL MEN [J].
FRANCIS, DP ;
HADLER, SC ;
THOMPSON, SE ;
MAYNARD, JE ;
OSTROW, DG ;
ALTMAN, N ;
BRAFF, EH ;
OMALLEY, P ;
HAWKINS, D ;
JUDSON, FN ;
PENLEY, K ;
NYLUND, T ;
CHRISTIE, G ;
MEYERS, F ;
MOORE, JN ;
GARDNER, A ;
DOTO, IL ;
MILLER, JH ;
REYNOLDS, GH ;
MURPHY, BL ;
SCHABLE, CA ;
CLARK, BT ;
CURRAN, JW ;
REDEKER, AG .
ANNALS OF INTERNAL MEDICINE, 1982, 97 (03) :362-366
[7]  
GOH KT, 1995, B WORLD HEALTH ORGAN, V73, P523
[8]  
GREUB G, 2000, IN PRESS VACCINE
[9]   LONG-TERM IMMUNOGENICITY AND EFFICACY OF HEPATITIS-B VACCINE IN HOMOSEXUAL MEN [J].
HADLER, SC ;
FRANCIS, DP ;
MAYNARD, JE ;
THOMPSON, SE ;
JUDSON, FN ;
ECHENBERG, DF ;
OSTROW, DG ;
OMALLEY, PM ;
PENLEY, KA ;
ALTMAN, NL ;
BRAFF, E ;
SHIPMAN, GF ;
COLEMAN, PJ ;
MANDEL, EJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1986, 315 (04) :209-214
[10]  
HUENGSBERG M, 1993, GENITOURIN MED, V69, P406